Results
In healthy subjects,following one week of paroxetine treatment there was a large increase in the cortisol response to 5-HTP.This increase had all but disappeared following 3 weeks treatment. In contrast, in depressed patients treated with paroxetine for 8 weeks, the cortisol response to 5-HTP was significantly increased.
Conclusions SSRItreatment in
depressed patients produces a persistent increase inthe cortisol response to 5-HTP a probable measure of neurotransmission at central 5-HT2 receptors. Potentiation of 5-HT2 neurotransmission is unlikely to account for the efficacy of SSRIsin major depression but might underlie their actions in obsessive-compulsive disorder and also perhaps certain of their adverse effects, notably sexual dysfunction.
In animal experimental studies, repeated administration of selective serotonin reuptake inhibitors (SSRIs) decreases the responsivity of post-synaptic 5-HT2 recep tors (Johnson, 1991) . However, repeated SSRI treatment also desensitises inhibitory 5-HT1A autoreceptors on 5-HT cell bodies which results in increased 5-HT neuronal firing and elevated extracellular levels of 5-HT in terminal regions (Blier &c de Montigny, 1994) . It is, therefore, difficult to predict what the net effect of these different changes might be on overall neurotransmis sion at post-synaptic 5-HT2 receptors. The aim of the present study was to assess the consequences of repeated SSRI treatment on 5-HT2 neurotransmission in humans by measuring the effect of paroxetine on the cortisol response to the 5-HT precursor, 5-hydroxytryptophan (5-HTP). This endo crine response involves indirect activation of post-synaptic 5-HT2 receptors (Gartside & Cowen, 1990; Gartside et al, 1992) and we therefore reasoned that it should pro vide a measure of overall neurotransmis sion at central 5-HT2 receptors.
METHOD
We carried out two studies involving administration of paroxetine, one in de pressed patients and the other in healthy volunteers. The patient group consisted of 10 out-patients (six female, four male) mean age 43.6 years (range 22-60 years) who on the basis of a standard clinical interview met DSM-III-R criteria for major depression. None had recent significant weight loss (>5 Ibs). One patient had been free of psychotropic medication for 2 weeks, the remaining subjects had been free of psychotropic drugs for at least 5 years. The 11 healthy subjects (four female, seven male; mean age 28.0 years, range 20-45 years) had no current or past history of psychiatric disorder. They had been free of psychotropic medication for at least 3 months. Subjects gave informed consent to the study which was approved by the local ethics committee.
Drug treatment
The depressed patients were treated with paroxetine at an initial dose of 20 mg daily. Treatment continued for 8 weeks before the second 5-HTP test (see below) when the mean paroxetine dose was 23 mg (range 20-30 mg). The healthy volunteers took 20 mg paroxetine daily for 3 weeks.
Neuroendocrine testing
Each 5-HTP neuroendocrine test was placebo-controlled whereby subjects received 5-HTP and placebo in a singleblind, randomised, cross-over fashion, one day apart. Healthy subjects were tested on three occasions: prior to paroxetine; after 6-7 days treatment; and after 20-21 days treatment. The female subjects had regular menstrual cycles and received their first and third 5-HTP tests at the same stage of their menstrual cycle. Depressed patients were tested on two occasions, before treatment and after 8 weeks treatment. One of the depressed patients was post-menopausal.
The remaining female subjects received their first and second 5-HTP tests at the same stage of their menstrual cycle.
Subjects were tested after an overnight fast at approximately 0900 h when an indwelling venous cannula was inserted and maintained with heparinised saline. Three baseline blood samples were taken over the next hour following which 5-HTP (100 mg orally) or placebo was adminis tered. Subsequently blood samples were removed at 20 minute intervals for the following 180 minutes for assay of plasma cortisol and 5-HTP.
Biochemical methods
Plasma was separated by centrifugation and stored at â€"30Â°C.Plasma cortisol was determined by radioimmunoassay (RIA). The intra-and inter-assay coefficients of variation over the range encompassed by the standard curve were 4.3 and 5.8%. 5-HTP in plasma was determined by isocratic reverse phase high performance liquid chromatography with amperometric detection.
Statistics
The cortisol response to placebo was subtracted from the cortisol response to 5-HTP to a give placebo-corrected cortisol response to 5-HTP. These data were analysed with a two-way repeated measures analysis of covariance (ANCOVA) with plasma levels of 5-HTP as a varying covariate. Significant two-way interactions (occasion by time) were then assessed by Fisher's test of least significant difference as a post-hoc range test. The placebocorrected cortisol response to 5-HTP was also measured as area under the curve (AUC) using the trapezoid method. These data were not normally distributed and were analysed by rank transformation followed by paired i-tests (two-tailed) (Conover & ImÃ¡n, 1981) . Plasma levels of 5-HTP were measured as AUC and analysed with paired i-tests (two-tailed). Correlations were car ried out using Pearson's product moment.
RESULTS

Healthy subjects
The ANCOVA of the placebo-corrected cortisol response to 5-HTP showed a sig nificant occasion by time interaction (F=2.95; d.f.=22,219; P<0.001). Post-hoc testing revealed that at the end of the first week of paroxetine treatment, cortisol responses to 5-HTP were strikingly en hanced. After a further 2 weeks the cortisol responses were substantially less and had almost returned to pre-paroxetine values (Fig. 1) . While some small differences be tween the latter two testing occasions were apparent on post-hoc testing ( Fig. 1) showed only a trend to a significant occa sion by time interaction (F=1.67; d.f.=ll,109;P=0.089).
When the cortisol response to 5-HTP was measured by AUC we found that the AUC (mean (SEM)) cortisol response to 5-HTP after one week of treatment (27.8 (8.6)ug/100 ml x h) was significantly great er than before paroxetine ( â€" 0.01 (4.5) ug/ lOOmlxh; P=0.005) and the response after 3 weeks treatment (9.0 (6.5); P=0.028). The AUC cortisol response be tween the pre-paroxetine test and that at 3 weeks treatment did not differ (P=0.23).
The AUC (mean (SEM)) of 5-HTP in plasma before paroxetine administration (128 (26) ng/ml x h) was significantly higher than after 7 days (73 (13) 
Depressed patients
The ANCOVA of the placebo-corrected cortisol response to 5-HTP showed a significant occasion by time interaction (F=3.41; d.f.=ll,98; P<0.001). Post-hoc testing showed that the cortisol responses to 5-HTP were significantly greater in depressed patients after 8 weeks of treat ment (Fig. 2) . The AUC (mean (SEM)) cortisol response to 5-HTP was signifi cantly greater after paroxetine treatment than before (16.7 (3.9) v. 6.0 (4.2) ug/ 100 mix h; P=0.048). The AUC of plasma 5-HTP in the patients was not altered by paroxetine treatment (pre-paroxetine=256 (38) ng/ ml x h; post-paroxetine=247 (55) ng/ mlxh; P>0.5). 5-HTP levels did not correlate significantly with cortisol re sponse to 5-HTP in either test (P>0.1).
Following paroxetine treatment, scores on the 17-item Hamilton Rating Scale for Depression (HAM-D) fell from a mean of 19.6 (range 16-22) to 9.5 (range 2-18) with six of the subjects achieving a reduc tion in HAM-D score of at least 50%.
There was no correlation between change in HAM-D score and increase in AUC cortisol response to 5-HTP (P>0.1). 
DISCUSSION
Our data show that short-term (one week) treatment with paroxetine in healthy sub jects leads to substantial increases in the cortisol response to 5-HTP. Following 3 weeks treatment, however, the response is considerably attenuated but may not have completely returned to pre-treatment levels.
In depressed patients treated for longer time periods (8 weeks) a clear and significant increase in 5-HTP-mediated cortisol release is apparent.
5-HTP as a neuroendocrine probe
The use of 5-HTP as a probe of 5-HT neuroendocrine function has methodologi cal drawbacks. For example, the metabo lism of 5-HTP to 5-HT is not confined to 5-HT neurones but can occur in other neuronal and non-neuronal tissues through out the body. For this reason plasma levels of 5-HTP are unlikely to be a good guide to 5-HTP concentrations in the brain and we found no correlation between plasma 5-HTP levels and cortisol response. Currently we are unable to explain the decrease in plasma 5-HTP levels during paroxetine treatment in healthy subjects; this change, however, was not apparent in the depressed patients. It is also worth noting that animals studies suggest that 5-HTP may be taken up into catecholaminergic neur ones where it can release dopamine and noradrenaline by displacement (Yatham &c Steiner, 1993) . Despite these reservations, both animal and human studies have found that 5-HTPinduced adrenocorticotrophic hormone and cortisol release is blocked by selective 5-HT2 receptor antagonists such as ritanserin and ketanserin but not by antagonists of other 5-HT receptor subtypes (Gartside & Cowen, 1990; Lee et al, 1991; Meltzer & Maes, 1994) . Moreover, the increase in extracellular 5-HT in rat hypothalamus following 5-HTP administration is depen dent on 5-HT neuronal firing (Gartside et al, 1992) . This suggests that the cortisol response to 5-HTP is probably mediated by release of 5-HT followed by indirect activa tion of post-synaptic 5-HT2 receptors.
SSRIs and 5-HTP-induced cortisol release in healthy subjects
The marked increase in 5-HTP-induced cortisol release we observed in healthy subjects after a week of paroxetine treat ment has to be received with some caution because we did not control for the stage of the menstrual cycle in this part of the study. Our observation, however, is con sistent with animal studies in which acute pre-treatment with SSRIs strongly potenti ates endocrine responses to 5-HTP (Fuller, 1981) . Following longer-term SSRI treat ment in animals, there is evidence of adaptive changes in post-synaptic 5-HT2 receptors. For example, behavioural re sponses to direct agonist stimulation of 5-HT2 receptors are attenuated and this may be associated with a decrease in the density of 5-HT2 receptors determined by ligand-binding experiments (see Johnson, 1991) . A process of post-synaptic 5-HT2 receptor down-regulation could well ac count for our finding that following 3 weeks SSRI treatment in healthy subjects, the cortisol responses to 5-HTP were significantly less than those seen after one week. The cortisol responses at this time were still possibly a little greater than those seen prior to paroxetine administra tion but it is not clear whether this relatively small effect would remain with continued treatment.
SSRIs and 5-HTP-induced cortisol release in depressed patients
Comparison of these neuroendocrine changes with those seen in depressed patients must be approached with caution because patients and controls were not matched for age and gender. However, in depressed patients a clear increase in 5-HTP-mediated cortisol release was appar ent following 8 weeks paroxetine treat ment, at which time antidepressant effects were well established. This suggests that in depressed patients, administration of SSRIs produces an enduring increase in brain 5-HT2 neurotransmission. Whether patients, like controls, have an early large increase in 5-HTP-mediated cortisol release which is then attenuated to some extent remains to be determined.
It is of interest that depressed patients and healthy subjects may show differing effects of SSRIs on some aspects of brain 5-HT neurotransmission.
A similar finding has been made in respect of tricyclic antidepressant and noradrenaline function where a 3-week period of desipramine treatment increased melatonin secretion in depressed patients but not in healthy controls (Thompson et al, 1985) . Presum ably these contrasting effects of antidepressants on brain 5-HT and noradrenaline are likely to reflect differences in the regulation of brain monoamine function between patients and healthy subjects.
The net effect of SSRIs on 5-HT neurotransmission probably involves a balance between a series of neuroadaptational changes in both pre-and postsynaptic 5-HT receptors. Some of these, for example, for the desensitisation of 5-HT1A cell body autoreceptors, should act to increase 5-HT neurotransmission (Blier & de Montigny, 1994) while others, such as post-synaptic 5-HT2 receptor downregulation, would produce the opposite effect (Johnson, 1991) . Our data suggest that the net effect of repeated SSRI treat ment in depressed patients is to increase neurotransmission at post-synaptic 5-HT2 receptors.
5-HT2 neurotransmission and antidepressant action
In contrast to SSRIs, certain other classes of antidepressants, particularly tertiary tricyclic antidepressants (TCAs) act as antagonists at 5-HT2 receptors (see Jenck et al, 1993) .
Consistent with this, repeated treatment of depressed patients with TCAs appears to lower the cortisol response to 5-HTP (Meltzer et al, 1984) , suggesting that SSRIs and TCAs produce opposite effects on neurotransmsision at 5-HT2 receptors. Be cause TCAs and SSRIs have generally equivalent clinical antidepressant potency (Anderson Ã"C Tomenson, 1994) , changes in brain 5-HT2 neurotransmission are unlikely to be relevant to the mode of action of antidepressant drugs in uncomplicated major depression.
In contrast repeated administration of both SSRIs and TCAs to depressed patients increase the prolactin responses to the 5-HT precursor, L-tryptophan (see Price et al, 1989 ). This response probably involves indirect activation of post-synaptic 5-HT1A receptors (Cowen, 1993) which have been implicated in mediating the antidepressant actions of TCA and SSRIs (Deakin & Graeff, 1991; Blier & de Montigny, 1994) .
Clinical actions of SSRIs and 5-HT2 neurotransmission
Might the potentiation of 5-HT2 neuro transmission be involved in any of the clinical actions that distinguish SSRIs from TCAs? With the exception of clomipramine, SSRIs are more effective than TCAs in the treatment of obsessive-compulsive disorder (see Piccinelli et al, 1995) . In this (Katsuda et al, 1993) , a common unwanted effect of SSRI treatment (Preskorn, 1995) . In addition, the anorgasmia produced by SSRIs is probably due to increased 5-HT2 neurotransmission because it can be ame liorated by treatment with 5-HT2 receptor antagonists such as cyproheptadine (Arnott & Nutt, 1994) .
